---
layout: post
title: "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-23457
original_published: 2022-10-28 00:00:00 +0000
significance: 8.00
---

# Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 28, 2022 00:00 UTC
**Document Number:** 2022-23457

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention." The purpose of this draft guidance is to assist sponsors in the clinical development of drugs for the treatment of Clostridioides difficile infection (CDI), reduction of recurrence, or prevention of CDI.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/28/2022-23457/clostridioides-difficile-infection-developing-drugs-for-treatment-reduction-of-recurrence-and)
- API: https://www.federalregister.gov/api/v1/documents/2022-23457

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
